April 2026 – Page 2 – An Overview of Extracellular and intracellular small-molecule AKT inhibitors

Apr 06 2026

Off

Con = control; M = blended Alzheimer VaD and disease; SND = heart stroke no dementia

By icmt24

Con = control; M = blended Alzheimer VaD and disease; SND = heart stroke no dementia. Body 3Changes in synaptic protein in vascular dementia (VaD) Concentrations of synaptophysin (A, B), EAAT2 (C, D), and vesicular glutamate transporter 1 (VGLUT1) (E, F) seeing that determined by American blotting in Brodmann region (BA) 9 (A, C, E)…

Apr 01 2026

Off

In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]

By icmt24

In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]. will have efficacy in more than a subset of tumors. Overcoming these therapeutic barriers will require multiple agents that can…

﻿Con = control; M = blended Alzheimer VaD and disease; SND = heart stroke no dementia

﻿In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]

Con = control; M = blended Alzheimer VaD and disease; SND = heart stroke no dementia

In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]